Number of participants with change in bone pain¹ assessed on VAS. · Paget's disease of bone
It is very uncertain whether zoledronate changes number of participants with change in bone pain¹ assessed on VAS. compared with pamidronate or risedronate (very low certainty).
1 finding from 1 review
Fracture · Paget's disease of bone
1 finding from 1 review
Intervention not reported
Joint mobility Range of motion Scale from 0°‐135° (higher number reflects better outcome) · people with neurological conditions1
1 finding from 1 review
Intervention not reported
Activity limitations 100‐point Disabilities of the Arm, Shoulder and Hand questionnaire (lower score reflects better outcome) · people with non‐neurological conditions1
1 finding from 1 review
Intervention not reported
Participation restrictions 100 mm return to usual work activities VAS (higher score reflects better outcome) · people with non‐neurological conditions1
1 finding from 1 review
Intervention not reported
Adverse events · people with non‐neurological conditions1
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life · people with neurological conditions1
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Pain 10‐point VAS (lower score reflects better outcome) · people with neurological conditions1
1 finding from 1 review
Intervention not reported
Activity limitations 18‐point upper limb scale (higher score reflects better outcome) · people with neurological conditions1
1 finding from 1 review
Intervention not reported
Participation restrictions · people with neurological conditions1
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events · people with neurological conditions1
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Joint mobility Range of motion Scale from 0°‐90° (higher number reflects better outcome) · people with non‐neurological conditions1
1 finding from 1 review
Intervention not reported
Quality of life 160‐point Burn Specific Health Scale‐Brief questionnaire (higher score reflects better outcome) · people with non‐neurological conditions1
1 finding from 1 review
Intervention not reported
Pain 10‐point VAS (lower score reflects better outcome) · people with non‐neurological conditions1
1 finding from 1 review
ACR 50% improvement · patients with rheumatoid arthritis in adults
Certolizumab pegol 200 mg sc (with or without MTX) leads to higher ACR 50% improvement compared with placebo (with or without MTX) (high certainty).
1 finding from 1 review
HAQ change from baseline Scale from: 0 to 3. · patients with rheumatoid arthritis in adults
Certolizumab pegol 200 mg sc (with or without MTX) showed no clear difference in HAQ change from baseline Scale from: 0 to 3. compared with placebo (with or without MTX) (moderate certainty).
1 finding from 1 review
DAS (low or remission) · patients with rheumatoid arthritis in adults
Certolizumab pegol 200 mg sc (with or without MTX) leads to higher proportion of patients achieving DAS < 2.6 (remission) compared with placebo (with or without MTX) (high certainty).
1 finding from 1 review
Radiological changes: Erosion Scores (ES) Scale from: 0 to 230. · patients with rheumatoid arthritis in adults
Certolizumab pegol 200 mg sc (with or without MTX) showed no clear difference in radiological changes: Erosion Scores (ES) Scale from: 0 to 230 compared with placebo (with or without MTX) (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with rheumatoid arthritis in adults
Certolizumab pegol 200 mg sc (with or without MTX) leads to higher serious adverse events compared with placebo (with or without MTX) (high certainty).
1 finding from 1 review
Acceptability: total withdrawals · patients with rheumatoid arthritis in adults
Certolizumab pegol 200 mg sc (with or without MTX) probably leads to lower all Withdrawals: All doses of certolizumab pegol vs placebo compared with placebo (with or without MTX) (moderate certainty).
1 finding from 1 review